Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | CETP | P11597 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932637 | 0.92 | DNM1 (0.43) | TP53SMN1; SMN2SIGMAR1DNM1CETP | |
| SCHEMBL9746323 | 0.88 | TP53 (0.42) | TP53SMN1; SMN2SIGMAR1 | |
| SCHEMBL3481939 | 0.82 | KCNH2 (0.46) | SMN1; SMN2SIGMAR1CETPMAPK1 | |
| SCHEMBL8575292 | 0.79 | TP53 (0.46) | TP53 | |
| SCHEMBL3237076 | 0.78 | TSHR (0.48) | TP53SMN1; SMN2 | |
| Benzene SCHEMBL28857166 | 0.78 | TSHR (0.33) | SMN1; SMN2PCSK9KMT2A | |
| SCHEMBL1315205 | 0.78 | TP53 (0.41) | TP53SMN1; SMN2SIGMAR1DNM1EPHX2 | |
| SCHEMBL27913020 | 0.77 | SMN1; SMN2 (0.34) | TP53SMN1; SMN2SIGMAR1DNM1CETP | |
| SCHEMBL27931013 | 0.77 | SMN1; SMN2 (0.34) | TP53SMN1; SMN2SIGMAR1DNM1CETP | |
| SCHEMBL15302323 | 0.76 | TP53 (0.39) | TP53SMN1; SMN2SIGMAR1DNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112280005-A | Organic silicon hybrid epoxy resin and preparation method thereof | 衡阳拓创聚合新材料有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-8791221-B2 | Addition-curable metallosiloxane compound | DAICEL CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2650319-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | Daicel Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | DAICEL CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| US-5100762-A | Radiation-sensitive polymer and radiation-sensitive composition containing the same | MITSUBISHI DENKI KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | B2M, MSI2, MNS1 | TP53 3501/4885SMN1; SMN2 353/4885SIGMAR1 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.